{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:59:41Z","timestamp":1776275981327,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jinf.2016.04.015","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T20:29:35Z","timestamp":1464467375000},"page":"S1-S5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"S","title":["Adjunctive therapies for Kawasaki disease"],"prefix":"10.1016","volume":"72","author":[{"given":"Anita J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2016.04.015_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/01.CIR.94.6.1379","article-title":"Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients","volume":"94","author":"Kato","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jinf.2016.04.015_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0022-3476(05)80742-5","article-title":"Nationwide survey of Kawasaki disease and acute rheumatic fever","volume":"119","author":"Taubert","year":"1991","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.015_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/00006454-199812000-00009","article-title":"Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US\/Canadian Kawasaki Syndrome Study Group","volume":"17","author":"Burns","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.jinf.2016.04.015_bib4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jpeds.2010.10.012","article-title":"Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study","volume":"158","author":"Son","year":"2011","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.015_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jpeds.2012.02.048","article-title":"Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"161","author":"Tremoulet","year":"2012","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.015_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/08916934.2015.1027818","article-title":"The role of statins in inflammatory vasculitides","volume":"48","author":"Tremoulet","year":"2015","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.015_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00431-011-1585-4","article-title":"A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease","volume":"171","author":"Zhu","year":"2012","journal-title":"Eur J Pediatr"},{"issue":"6","key":"10.1016\/j.jinf.2016.04.015_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.015_bib9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1136\/annrheumdis-2012-201658","article-title":"A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation","volume":"71","author":"Cohen","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9826","key":"10.1016\/j.jinf.2016.04.015_bib10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","article-title":"Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial","volume":"379","author":"Kobayashi","year":"2012","journal-title":"Lancet"},{"issue":"9433","key":"10.1016\/j.jinf.2016.04.015_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(04)16814-1","article-title":"Kawasaki syndrome","volume":"364","author":"Burns","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jinf.2016.04.015_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1586\/1744666X.2015.1044980","article-title":"The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease","volume":"11","author":"Burns","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jinf.2016.04.015_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/08916934.2013.860524","article-title":"Specificity of regulatory T cells that modulate vascular inflammation","volume":"47","author":"Franco","year":"2014","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.jinf.2016.04.015_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/cei.12182","article-title":"Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin","volume":"174","author":"Burns","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.jinf.2016.04.015_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1924.02650330034013","article-title":"The significance of Streptococcus hemolyticus in scarlet fever","volume":"82","author":"Dochez","year":"1924","journal-title":"J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.jinf.2016.04.015_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jama.1925.02660370013007","article-title":"Therapeutic results with concentrated scarlet fever antitoxin","volume":"84","author":"Dick","year":"1925","journal-title":"J Am Med Assoc"},{"issue":"9","key":"10.1016\/j.jinf.2016.04.015_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.1924.02650350044017","article-title":"Observations on the treatment of scarlet fever with scarlatinal antistreptococcic serum","volume":"82","author":"Blake","year":"1924","journal-title":"J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.015_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2007.12.021","article-title":"Resistance to intravenous immunoglobulin in children with Kawasaki disease","volume":"153","author":"Tremoulet","year":"2008","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.015_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/INF.0b013e318266bcf9","article-title":"Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease","volume":"31","author":"Dominguez","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.jinf.2016.04.015_bib20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0022-3476(05)80972-2","article-title":"Gamma globulin re-treatment in Kawasaki disease","volume":"123","author":"Sundel","year":"1993","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jinf.2016.04.015_bib21","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1017\/S1047951114002601","article-title":"A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease","volume":"25","author":"Yang","year":"2015","journal-title":"Cardiol Young"},{"issue":"Suppl. 2","key":"10.1016\/j.jinf.2016.04.015_bib22","first-page":"S90","article-title":"Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease","volume":"55","author":"Luban","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.jinf.2016.04.015_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1546-0096-10-10","article-title":"Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases","volume":"10","author":"Berard","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"issue":"22","key":"10.1016\/j.jinf.2016.04.015_bib24","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","article-title":"Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease","volume":"113","author":"Kobayashi","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jinf.2016.04.015_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2010.10.031","article-title":"Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance","volume":"158","author":"Sleeper","year":"2011","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.jinf.2016.04.015_bib26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/archdischild-2014-307397","article-title":"Predicting IVIG resistance in UK Kawasaki disease","volume":"100","author":"Davies","year":"2015","journal-title":"Arch Dis Child"},{"issue":"9930","key":"10.1016\/j.jinf.2016.04.015_bib27","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","article-title":"Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"383","author":"Tremoulet","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.015_bib28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1161\/CIRCULATIONAHA.111.072769","article-title":"Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease","volume":"125","author":"Lee","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jinf.2016.04.015_bib29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s13073-014-0102-6","article-title":"Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease","volume":"6","author":"Hoang","year":"2014","journal-title":"Genome Med"},{"issue":"26","key":"10.1016\/j.jinf.2016.04.015_bib30","article-title":"High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report","volume":"12","author":"Shafferman","year":"2014","journal-title":"Pediatr Rheumatol Online"},{"issue":"5","key":"10.1016\/j.jinf.2016.04.015_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1203\/PDR.0b013e31819dba60","article-title":"Molecular genetics of Kawasaki disease","volume":"65","author":"Onouchi","year":"2009","journal-title":"Pediatr Res"},{"issue":"10","key":"10.1016\/j.jinf.2016.04.015_bib32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/INF.0b013e318220c3cf","article-title":"Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin","volume":"30","author":"Suzuki","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.jinf.2016.04.015_bib33","doi-asserted-by":"crossref","first-page":"e009562","DOI":"10.1136\/bmjopen-2015-009562","article-title":"Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)","volume":"5","author":"Aoyagi","year":"2015","journal-title":"BMJ Open"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445316300421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445316300421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:22:39Z","timestamp":1759008159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445316300421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":33,"alternative-id":["S0163445316300421"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2016.04.015","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive therapies for Kawasaki disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2016.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}